Faster global financial news!
Johnson & Johnson
-
Yahoo Finance Analysis: Coca-Cola, Johnson & Johnson, and PepsiCo are three dividend stocks worth holding for Baby Boomers.
Yahoo Finance analysis indicates that Coca-Cola (KO), Johnson & Johnson (JNJ), and PepsiCo (PEP) are three dividend stocks suitable for Baby Boomer investors to hold for life. These companies boast de
-
Johnson & Johnson Targets Double-Digit Growth by End of Decade, Projects Over $100 Billion Revenue in 2026
Johnson & Johnson raised its growth ambitions, forecasting 6.5% adjusted operational sales growth and 7.3% adjusted EPS growth in 2026, with revenue expected to surpass $100 billion for the first time
-
Johnson & Johnson MedTech Chairman Tim Schmid: Confident in High-End Growth, Cardiovascular to Be Largest Business by Q1 2027
Johnson & Johnson (JNJ) MedTech Chairman Tim Schmid stated the company is confident in achieving the high end of its 5% to 7% operational market-growth range for 2022-2027. He highlighted a portfolio
-
LB Pharmaceuticals (LBRX) IPO Stock Has Tripled In Under A Year, Prompting Speculation It Could Be A Takeover Target
The small biotech company, which is based in New York, has one drug called LB-102, an oral formulation of the antipsychotic benzamide, and is working to challenge Bristol Myers Squibb (BMY) and Johnso
-
Yahoo Finance: Coca-Cola, Johnson & Johnson, and Procter & Gamble are 'Dividend Kings' trusted by retirees
According to Yahoo Finance analysis, Coca-Cola (KO), Johnson & Johnson (JNJ), and Procter & Gamble (PG) have consistently increased dividends through every U.S. recession since 1970, making them relia
-
Analysis shows Johnson & Johnson's latest 13F filing reveals holdings in 15 biotech stocks, with Protagonist Therapeutics being the largest investment, whose stock price has surged 65% year-to-date.
According to Yahoo Finance analysis, Johnson & Johnson's latest 13F filing (as of June 30, 2026) disclosed its holdings of 15 stocks in the biotechnology and medical technology sectors. The analysis i
-
AbbVie is considered a better healthcare stock pick than Johnson & Johnson for 2026, with its net income projected to surge to $14.6 billion.
An analysis from Yahoo Finance highlights AbbVie's impressive R&D pipeline and higher upside potential, projecting its net income to surge from $4.2 billion to $14.6 billion this fiscal year, with sal
-
Seaport Therapeutics (SPTX) is attracting interest from large pharmaceutical companies after its IPO, with its lead candidate drug GlyphAllo expected to announce Phase 2b topline data in the first half of 2027.
Analysis indicates that biopharmaceutical company Seaport Therapeutics (SPTX) has attracted attention from major pharmaceutical companies such as Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ)
-
Eli Lilly and J&J bounce on new data, as software stocks give up last week's gains
Eli Lilly and J&J bounce on new data, as software stocks give up last week's gains
-
Yahoo Finance analysis points out that three healthcare stocks, Eli Lilly, Johnson & Johnson, and AbbVie, are worth watching in August due to their relatively poor market performance but strong fundamentals.
The analysis suggests that although the healthcare sector has underperformed the S&P 500 year-to-date, it has led all sectors over the past three months. Specifically, Eli Lilly's Q2 revenue increased
-
Analysis identifies Johnson & Johnson, Coca-Cola, and ExxonMobil as top dividend stock buys for H2 2026
An analysis suggests Johnson & Johnson (JNJ), Coca-Cola (KO), and ExxonMobil (XOM) are strong dividend stock buys for the second half of 2026. The report highlights their consistent dividend growth, r
-
Yahoo Finance Analysis: Coca-Cola, Johnson & Johnson, and PepsiCo are three dividend stocks worth holding for Baby Boomers.
Yahoo Finance analysis indicates that Coca-Cola (KO), Johnson & Johnson (JNJ), and PepsiCo (PEP) are three dividend stocks suitable for Baby Boomer investors to hold for life. These companies boast de
-
Johnson & Johnson Targets Double-Digit Growth by End of Decade, Projects Over $100 Billion Revenue in 2026
Johnson & Johnson raised its growth ambitions, forecasting 6.5% adjusted operational sales growth and 7.3% adjusted EPS growth in 2026, with revenue expected to surpass $100 billion for the first time
-
Johnson & Johnson MedTech Chairman Tim Schmid: Confident in High-End Growth, Cardiovascular to Be Largest Business by Q1 2027
Johnson & Johnson (JNJ) MedTech Chairman Tim Schmid stated the company is confident in achieving the high end of its 5% to 7% operational market-growth range for 2022-2027. He highlighted a portfolio
-
LB Pharmaceuticals (LBRX) IPO Stock Has Tripled In Under A Year, Prompting Speculation It Could Be A Takeover Target
The small biotech company, which is based in New York, has one drug called LB-102, an oral formulation of the antipsychotic benzamide, and is working to challenge Bristol Myers Squibb (BMY) and Johnso
-
Yahoo Finance: Coca-Cola, Johnson & Johnson, and Procter & Gamble are 'Dividend Kings' trusted by retirees
According to Yahoo Finance analysis, Coca-Cola (KO), Johnson & Johnson (JNJ), and Procter & Gamble (PG) have consistently increased dividends through every U.S. recession since 1970, making them relia
-
Analysis shows Johnson & Johnson's latest 13F filing reveals holdings in 15 biotech stocks, with Protagonist Therapeutics being the largest investment, whose stock price has surged 65% year-to-date.
According to Yahoo Finance analysis, Johnson & Johnson's latest 13F filing (as of June 30, 2026) disclosed its holdings of 15 stocks in the biotechnology and medical technology sectors. The analysis i
-
AbbVie is considered a better healthcare stock pick than Johnson & Johnson for 2026, with its net income projected to surge to $14.6 billion.
An analysis from Yahoo Finance highlights AbbVie's impressive R&D pipeline and higher upside potential, projecting its net income to surge from $4.2 billion to $14.6 billion this fiscal year, with sal
-
Seaport Therapeutics (SPTX) is attracting interest from large pharmaceutical companies after its IPO, with its lead candidate drug GlyphAllo expected to announce Phase 2b topline data in the first half of 2027.
Analysis indicates that biopharmaceutical company Seaport Therapeutics (SPTX) has attracted attention from major pharmaceutical companies such as Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ)
-
Eli Lilly and J&J bounce on new data, as software stocks give up last week's gains
Eli Lilly and J&J bounce on new data, as software stocks give up last week's gains
-
Yahoo Finance analysis points out that three healthcare stocks, Eli Lilly, Johnson & Johnson, and AbbVie, are worth watching in August due to their relatively poor market performance but strong fundamentals.
The analysis suggests that although the healthcare sector has underperformed the S&P 500 year-to-date, it has led all sectors over the past three months. Specifically, Eli Lilly's Q2 revenue increased
-
Analysis identifies Johnson & Johnson, Coca-Cola, and ExxonMobil as top dividend stock buys for H2 2026
An analysis suggests Johnson & Johnson (JNJ), Coca-Cola (KO), and ExxonMobil (XOM) are strong dividend stock buys for the second half of 2026. The report highlights their consistent dividend growth, r
- No data
Johnson & Johnson
24H Trending
-
1
SK hynix in talks with Intel over potential US memory production agreement
-
2
Fetch.ai (FET) Token Analysis: Project Status and Investment Considerations
-
3
XLM Price Analysis: Stellar Lumens' Positioning, Progress, and Market Outlook
-
4
Bybit to adjust risk limits and leverage for selected perpetual contracts including 1000XECUSDT and BLASTUSDT, effective Sep 18, 2026
-
5
Zhipu AI's CoWork business in China is progressing rapidly, with industry orders exceeding 1 billion yuan within one month of GLM-5.3's release.
-
6
Anthropic, after calling for an AI slowdown, has signed its first data center lease in Australia, planning a total capacity of 2.16 GW.
-
7
Nikkei: Japan's MUFG Bank to Introduce Guidelines for Financing Defense Industry
-
8
Turkish Stocks Fall More Than 5% Amid Deepening Fund Redemption Woes
-
9
Markets are cautiously optimistic ahead of the Federal Reserve's decision, with U.S. Treasuries slightly stronger, crude oil gains narrowing, and equity index futures holding steady.
-
10
UK FCA Issues New Guidance for Crypto Assets, Preparing Firms for Authorization Applications Opening September 2026
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
